Javier Gutiérrez

Mr. Javier Gutiérrez

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RVReinaldo Vallejo
Reinaldo Vallejo
Daniela Alejandra QuinterosDaniela Alejandra Quinteros
Daniela Alejandra Quinteros
JGJavier Gutiérrez
Javier Gutiérrez
SMSofía Martínez
Sofía Martínez
SRSoraya Rodríguez Rojo
Soraya Rodríguez Rojo
FAF. Javier Arias
F. Javier Arias

31 January 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CHCarla Hernando-Muñoz
Carla Hernando-Muñoz
ARAndrea Revilla-Cuesta
Andrea Revilla-Cuesta
IAIrene Abajo-Cuadrado
Irene Abajo-Cuadrado
CACamilla Andreini
Camilla Andreini
Tomás TorrobaTomás Torroba
Tomás Torroba
RPRobert Pal
Robert Pal

7 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
Juan Gonzalez-Valdivieso
JGJavier Gutiérrez
Javier Gutiérrez
Jonathan Alexander Vasquez CaleroJonathan Alexander Vasquez Calero
Jonathan Alexander Vasquez Calero
Sara EscaleraSara Escalera
Sara Escalera
RMRaquel Muñoz-Martínez
Raquel Muñoz-Martínez
Alessandra GirottiAlessandra Girotti
Alessandra Girotti
Over the past decade, the use of nanomaterials and nanomedical devices has been increasingly explored for cancer treatment. Although the outcomes of conventional therapies have improved patient survival, these approaches still present important limitations for some types of cancer and metastasis. Challenges such as poor drug accumulation in solid tumors and lack of specificity and selectivity can be addressed through alternative nanomedicine-based treatments. Among the wide range of nanoplatforms whose composition and shape have been designed for cancer treatment, this review focuses specifically on those based on natural proteins, including advanced carriers and engineered proteins bearing active targeting and/or therapeutic agents. The objective of this review is to provide a comparative and translational analysis of protein-based nanomaterials for cancer therapy, highlighting their unique characteristics, such as biocompatibility, biodegradability, and the ability to integrate bioactive peptides that can trigger or respond to tumor-specific or altered physiological stimuli. Several protein-based nanomedical devices have been developed for theranostic applications, demonstrating enhanced performance in tumor imaging and cancer treatment. This review introduces a structured analytical framework that classifies protein-based nanomaterials according to their biological origin, functional design, and clinical readiness, enabling systematic evaluation across platforms. Rather than providing a descriptive overview, this work offers a structured comparative analysis of protein-based nanomaterials, highlighting design trade-offs, translational challenges, and factors influencing clinical applicability.